NeurAxis Q3 revenue up 22% YoY to $811,000, operating loss rises 27%.

• NeurAxis Q3 revenue up 22% YoY to $811,000 • Operating loss increased 27% YoY to $3.2 million • Cash balance at $4.4 million as of Sept. 30, 2025 • FDA clearance for pain treatment in adult Functional Dyspepsia patients • Academic society guidelines recommendation secured • Additional $2.8 million secured through at-the-market equity offering